Jakafi (ruxolitinib)

Jakafi (Ruxolitinib) is a selective Janus kinase (JAK) 1 and JAK2 inhibitor developed to treat specific hematologic disorders and immune-mediated conditions. By targeting the JAK-STAT signaling pathway, which plays a critical role in blood cell production and immune regulation, Jakafi helps reduce disease activity, control symptoms, and improve overall patient outcomes.

Jakafi is approved for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis and myelofibrosis associated with polycythemia vera or essential thrombocythemia. It is also indicated for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. In addition, Jakafi is used in the management of acute and chronic graft-versus-host disease (GVHD) after failure of one or more prior therapies.

Administered orally, Jakafi provides a convenient treatment option and has demonstrated significant clinical benefits, including reduction in spleen size, improvement in disease-related symptoms, and enhanced quality of life for many patients. In graft-versus-host disease, it helps modulate excessive immune activity, contributing to improved disease control and patient management.

As a pioneering JAK inhibitor, Jakafi has transformed the treatment landscape for several blood disorders and immune-mediated diseases. Its targeted mechanism of action, proven clinical efficacy, and broad therapeutic applications make it an important treatment option in modern hematology and specialized patient care.